So far, frequently, the only available response to emerging resistance has been the increase in 'firepower', i.e., enhanced doses of the therapeutics.
The discrepancy remains unexplained, but still suggests that the need for enhanced dose intensity of oxaliplatin above 85 mg m−2 requires exploration.
Such materials can provide several advantages such as a high-packing density, which can lead to enhanced dosing, an increased flexibility of design as these materials naturally interact biologically and a lack of void volume as whole particles can be designed to be active.
Increased free radical production at various doses of DEP would result in impairment of the defense system leading to an enhanced dose-dependent reproductive toxic effect.
In order to account for degradation of the prescribed dose gradient at the edge of moving target volumes during delivery, patient-specific margins that consist of edge-enhanced dose intensity maps can be constructed[85].
In this study, conducted under experimental conditions, a single dose of LIXI enhanced first-phase insulin secretion by 2.8-fold and second-phase insulin secretion by 1.6-fold in response to an iv glucose challenge in people with T2DM.
A challenge dose of apomorphine showed enhanced rotational response in rats pretreated with methyl levodopa.
Under in vitro experimental conditions, exposure to a subcytotoxic dose of IL-1β enhanced human gingival fibroblast inflammation, as characterized by increased levels of inflammation-associated proteins.
The 250 mg/m rituximab dose was chosen as the dose to be given before RIT because no difference in imaging or dosimetry was observed between dosing groups, and there was potential for enhanced clinical response from the higher dose of rituximab.
However, IL-32β enhances the cellular response to very low dose of cytokine stimulation, which results in enhanced leukocyte adhesion.
